WO2003046185A1 - Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers - Google Patents
Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers Download PDFInfo
- Publication number
- WO2003046185A1 WO2003046185A1 PCT/US2002/020565 US0220565W WO03046185A1 WO 2003046185 A1 WO2003046185 A1 WO 2003046185A1 US 0220565 W US0220565 W US 0220565W WO 03046185 A1 WO03046185 A1 WO 03046185A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carrier
- hydrophilic backbone
- biocompatible hydrophilic
- polycationic polymers
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
Definitions
- the present invention relates to the transport of biologically active agents across biological barriers. More specifically, the present invention relates to methods and compositions that enhance transport of polyanionic macromolecules such as DNA, RNA, antisense oligonucleotides and their analogs across biological barriers.
- polyanionic macromolecules such as DNA, RNA, antisense oligonucleotides and their analogs across biological barriers.
- Gene therapy and antisense technology have been highly promoted for their potential to treat or cure a number of diseases. Many viral diseases and genetic conditions can potentially be treated by gene therapy. A great number of genes that play a role in previously untreatable diseases such as cancer, autoimmune diseases, cystic fibrosis and the like have been discovered. With the discovery of the gene involved, researchers have determined that the disease can be treated by either blocking a gene that is being over- expressed or by providing a copy of a malfunctioning gene. Often these treatments require the administration of DNA, RNA, antisense oligonucleotides, and their analogs to achieve a desired intracellular effect.
- macromolecules such as DNA, RNA, antisense oligonucleotides, and their analogs share similar, significant pharmaceutical problems. While these compounds are generally not toxic, if there are admistered orally, they do not reach the desired site because they are digested and metabolized. Injection of these polyanionic macromolecules increases the length of time the molecules are in the body, but does not target the specific area of need. Moreover they are subject to rapid degradation within the blood stream and clearance from the body. Because DNA, RNA, and oligonucleotides are polyanionic macromolecules they do not readily cross biological barriers. The transfer of these materials into living cells is the major impediment to their use as therapeutic agents.
- An effective gene and oligonucleotide delivery system will need to bind to an appropriate cell, be internalized by endocytosis, escape from the lysosome and ultimately transfer the intact free DNA or oligonucleotides to the nucleus or plasma.
- the success of gene therapy and antisense therapy is largely dependent on achieving a delivery of nucleic acids in sufficient quantities, to the correct target site of action, and for the desired time frame.
- PEI polycationic polymer
- PEI is a highly polycationic synthetic polymer. It has been used for years in common processes such as paper production, shampoo manufacturing, and water purification. Recently, PEI has become one of the most successful polycation carriers used in oligonucleotide and DNA delivery. PEI has been shown to be a highly efficient carrier for delivering oligonucleotides and plasmids, both in vitro and in vivo. PEI is available in both linear and branched forms.
- PEI Because of its high positive charge density, PEI spontaneously forms interpolyelectrolyte complex (Polyion complex) with nucleic acid as a result of cooperative electrostatic interaction between the ammonium groups of the PEI and the phosphate groups of the nucleic acid.
- Polyion complex interpolyelectrolyte complex
- the ability of PEI to transfect a wide variety of cells is well established. Compared to other polycationic carriers, PEI has proved to be much better in protecting against nucleic acid degradation and releasing the nucleic acid to the cytoplasm after endocytosis.
- PEI is not a perfect transfecting agent.
- the PEI/NA complex usually produces serious aggregations in physiological buffers.
- the complexes show limited stability in the presence of serum and are rapidly cleared out of the bloodstream following systemic administration.
- PEI has been consistently observed to be toxic both in vitro and in vivo. These properties have significantly limited the biomedical applications of PEIs.
- the polymer has been conjugated or grafted with both hydrophilic and hydrophobic groups. Grafting of the PEIs with PEG results in copolymers that can form relatively stable DNA complexes in aqueous buffers. However, transfection activity of these systems is much lower than that of unmodified PEI (25kDa). Partially propionyl acylated liner PEI (50kDa and 200 kDa) also shows less toxicity, but again this modification compromises the transfection activity.
- a further advancement would be achieved if the carrier molecule showed reduced toxicity as compared to presently available compounds. It would be a further advancement if the carrier/macromolecule complex were stable exhibited serum stability. It would be a further advancement if carrier/macromolecule complex could readily disassociate within the target cell. It would be a further advancement to provide a carrier molecule that could be targeted to a specific tissue or cell type.
- This invention provides a novel class of polycation grafted biocompatible copolymers which can be used as carrier molecules to deliver a polyanionic macromolecule to a cell.
- Two or more polycationic polymer fragments are covalently linked to a biocompatible hydrophilic backbone polymer by linkers.
- the number of polycationic polymer fragments bound to the backbone polymer may be in the range from about 4 to about 100. It has been found that a number of polycationic fragments in the range from about 8 to about 15 can be successfully used to bind a polyanionic macromolecule and transfer the polyanionic macromolecule across biological barriers such as a cell wall or a plasma membrane.
- a variety of biocompatible polymers may be used as the backbone polymer.
- the backbone polymer may be, for example, polyethylene glycol (PEG), poly (N-(2- hydroxylpropyl)methacrylamide), or copolymers thereof.
- PEG polyethylene glycol
- PAM polyethylene glycol
- PEI polyethylenimine
- PL polylysine
- the carrier molecule may also include at least one targeting moiety connected to the biocompatible hydrophilic backbone or to the polycationic polymer.
- the targeting moiety can be selected to bind to a specific biological substance or site.
- the targeting moiety can be chosen based on its ability to bind to a molecule expressed in a specific cell type or specific tissue allowing the polyanionic macromolecule to be selectively delivered to the cell or tissue.
- Such targeting moieties may include a ligand, an antigen, a hapten, biotin, lectin, galactose, galactosamine, a protein, a histone, a polypeptide, a lipid, a carbohydrate, a vitamin, and a combination thereof.
- the carrier molecule may also include at least one lysis agent connected to the biocompatible hydrophilic backbone or to the polycationic polymer.
- the lysis agent can be selected to break down a biological membrane such as a cell, endosomal, or nuclear membrane, thereby allowing the polyanionic macromolecule to be released into the cytoplasm or nucleus of the cell.
- Such lysis agents may include a viral peptide, a bacterial toxin, a lytic peptide, aleveolysin, bifermentolysin, boutulinolysin, capriciolysin, cereolysin O, chauveolysin, histolyticolysin O, pneumolysin, sealigerolysin, septicolysin O, sordellilysin, streptoslysin O, tenaolysin or thuringolysin O, and active fragments thereof.
- the polycationic polymers are covalently linked to the biocompatible backbone polymer by linkers.
- the targeting moiety and the lysis agent may also be covalently linked to the backbone polymer by a linker.
- linkers can be a hydrocarbon chain, a PEG fragment, a polypeptide, a linear polymer containing an ester bond, a linear polymer containing an amide bond, a linear polymer containing a disulfide bond, a linear polymer containing a hydrozone bond, a linear polymer containing an oxime bond or a combination thereof.
- the linkers can be biodegradable peptides that can be broken by chemicals or enzymes to release the polycationic polymer, the targeting moiety, or the lysis agent from the backbone polymer.
- biodegradable peptide examples include GlyPheLeuGly (SEQ. ID. NO.: 1) and GlyPhePheGly (SEQ ID. NO.: 2).
- the linkers can have a length from about 2 to about 100 atoms. Linkers with a length of about 3 atoms to about 30 atoms can also be used.
- the biocompatible hydrophilic backbone can have a molecular weight that is selected to optimize the delivery of the polyanionic macromolecule to the cell.
- the backbone polymer has a molecular weight in the range from about 1,000 to about 1 ,000,000.
- a backbone polymer with a molecular weight in the range from about 5,000 to about 100,000 may also be used.
- a biocompatible hydrophilic backbone with a molecular weight of about 20,000 to about 40,000 can be used to deliver the polyanionic macromolecule to the cell.
- the molecular weight of the polycationic polymers can also be selected for optimal delivery of the polyanionic macromolecule to the target cell.
- the molecular weight can be in the range from about 100 about 100,000.
- the molecular weight of the polycationic polymers can be in the range from about 200 to about 10,000.
- a polycationic polymer with a molecular weight in the range from about 400 to about 2,000 can be used to deliver the polyanionic macromolecule to the cell.
- the present invention also relates to a complex for delivering a polyanionic macromolecule to a cell.
- the complex may have a carrier molecule as described above complexed with a polyanionic macromolecule.
- the complex may be given to an animal in vivo or a cell culture.
- the complex allows the polyanionic macromolecule to be delivered to the a cell within the animal or cell culture.
- the polyanionic macromolecule can be selected from a number of macromolecules that are useful in the treatment of disease or in laboratory experimentation.
- the polyanionic macromolecule is a nucleic acid such as RNA, DNA, or a combination or derivative thereof.
- the nucleic acid can be, for example, genomic DNA, plasmid DNA, synthetic DNA, or RNA.
- the invention also provides a method of transporting a polyanionic macromolecule across a biological barrier of a cell.
- the biological barrier can be a cell wall, a plasma membrane, or like cell membrane.
- the cell may be for example a cell in a cell culture.
- the cell may be a cell within a multicellular organism such as a plant or an animal.
- the cell can be a cell derived from an organism such as hepatocytes, liver cells, kidney cells, brain cells, bone marrow cells, nerve cells, heart cells, spleen cells, stem cells and co-cultures of the above.
- the cells may be from established cell lines such a HepG Hep G2 and Hela cells.
- the method of transporting the polyanionic macromolecule across the barrier includes complexing the polyanionic macromolecule to a carrier molecule of the present invention to create a complex.
- the cell is then contacted with the carrier molecule to deliver the polyanionic macromolecule to the cell.
- the complex is then taken into the cell by, for example, endocytocis and then released into the cell cytoplasm.
- Figure 1A is a schematic representation of the synthesis of one embodiment of a polycation grafted biocompatible copolymer of the present invention.
- Figure IB is a schematic representation of the synthesis of another embodiment of a polycation grafted biocompatible copolymer of the present invention.
- This invention provides a novel class of polycation grafted biocompatible copolymers which can be used as carrier molecules to deliver a polyanionic macromolecule to a cell.
- Two or more polycationic polymer fragments are randomly covalently linked to a biocompatible hydrophilic backbone polymer by a linker.
- the number of polycationic polymer fragments bound to the backbone polymer may be in the range from about 4 to about 100. It has been found that a number of polycationic fragments in the range from about 8 to about 15 can be successfully used to bind a polyanionic macromolecule and transfer the polyanionic macromolecule across biological barriers.
- biocompatible refers to a substance that has limited immunogenic and allergenic ability.
- Biocompatible also means that the substances does not cause significant undesired physiological reactions.
- a biocompatible substance may be biodegradable.
- biodegradable means that a substance such as the backbone polymer or the polycationic polymer can chemically or enzymatically break down or degrade within the body.
- a biodegradable substance may form nontoxic components when it is broken down.
- the biocompatible substance can be biologically neutral, meaning that it lacks specific binding properties or biorecognition properties.
- the backbone polymer may be, for example, polyethylene glycol (PEG), poly (N-(2- hydroxylpropyl)methacrylamide), or copolymers thereof.
- PEG polyethylene glycol
- PAM polyethylene glycol
- PEI polyethylenimine
- PL polylysine
- PEG has many qualities that make it a desirable biocompatible backbone polymer for use with the carrier polymers of the invention.
- PEG is commercially available in a variety of molecular masses at low dispersity (Mw/Mn ⁇ 1.1). Based on their molecular size, PEG polymers are arbitrarily classified into low molecular weight PEG (Mw ⁇ 20,000) and high molecular weight PEG (Mw>20,000).
- Mw ⁇ 20,000 low molecular weight
- Mw>20,000 high molecular weight
- the carrier molecule may also include at least one targeting moiety connected to the biocompatible hydrophilic backbone or to a bound polycationic polymer.
- the targeting moiety can be selected to bind to a specific biological substance or site herein referred to as the receptor.
- the targeting moiety can be chosen based on its ability to bind to a receptor molecule expressed in a specific cell type or specific tissue allowing the polyanionic macromolecule to be selectively delivered to the cell or tissue.
- the targeting moiety can be any signal member which is recognizable by a cell membrane receptor.
- the targeting moiety is a galtactose containing saccharide which specifically binds to liver cells or hepatoma cells.
- the galactose containing sacchride can be selected from the group consisting of lactose and galactose.
- a targeting moiety refers to those moieties that bind to a specific biological substance or site. The biological substance or site is considered the target of the targeting moiety that binds to it.
- Ligands are one type of targeting moiety. Ligands have a selective (or specific) affinity for another substance known as the receptor.
- the ligand has a specific affinity for the receptor, the ligand binds to the receptor selectively over other molecules.
- the carrier polymer can be designed to bind to a receptor on a specific cell type. This selective binding allows for the selective delivery of the polyanionic macromolecule to the target cell.
- ligands suitable for targeting cells are antigens, haptens, biotin, biotin derivatives, lectins, galactose, galactosamine vitamin and fucosylamine moieties, receptors, substrates, coenzymes and cofactors among others.
- a ligand When applied to the polycation grafted copolymers of this invention, a ligand includes an antigen or hapten that is capable of being bound by, or to, its corresponding antibody or an active fraction thereof. Also included are viral antigens or hemagglutinins and neuraminidases and nucleocapsids including those from any DNA viruses, RNA viruses, HIV, hepatitis viruses, adenoviruses, alphaviruses, arenaviruses, coronaviruses, flaviviruses, he ⁇ esviruses, myxoviruses, oncomaviruses, papovaviruses, paramyxoviruses, parvoviruses, picornaviruses, poxviruses, reoviruses, rhabdoviruses, rhinoviruses, togaviruses, and viriods.
- the ligand may be selected from any bacterial antigens including those of gram- negative and gram-positive bacteria, acinetobacter, achromobacter, bacteroides, clostridium, chlamydia, enterobacteria, haemophilus, lactobacillus, neisseria, staphyloccus, and streptoccocus.
- Other suitable ligands include any fungal antigens such as those of aspergillus, Candida, coccidiodes, mycoses, phycomycetes, and yeasts.
- antigens such as mycoplasma antigens, rickettsial antigens, protozoan antigens, and parasite antigens are suitable ligands in certain embodiments of the invention.
- Human antigens including those of blood cells, virus infected cells, genetic markers, oncoproteins, plasma proteins, complement factors, alphafetoprotein, prostate specific antigen (PSA), cancer markers, and rheumatoid factors may also serve as suitable ligands.
- PSA prostate specific antigen
- cancer markers and rheumatoid factors
- rheumatoid factors There are many other substances that may be used as appropirate ligands to direct the carrier copolymer to the target cell.
- Ligands also refers to various substances with selective affinity for a that are produced through recombinant DNA, genetic and molecular engineering.
- the receptor for a ligand is an important consideration in selecting a ligand to target a cell.
- the receptor may also be referred to as a ligator, binding body, or a binding partner.
- the receptor functions as a type of biorecognition molecule that selectivley binds to the ligand.
- the receptor is molecule that is generally, but not necessarily, larger than the ligand that binds it.
- a receptor can be a protein such as an antibody or a non-protein binding body.
- an antibody refers to all classes of antibodies including monoclonal antibodies, chimeric antibodies, Fab fractions, and derivatives thereof.
- Other receptors suitable for targeting include naturally occurring receptors, hemagglutinins, and cell membrane and nuclear derivatives that bind specifically to hormones, vitamins, drugs, antibiotics, cancer markers, genetic markers, viruses, and histocompatibility markers.
- receptors include RNA and DNA binding proteins.
- Other potentially useful receptors for targeting are cell surface enzymes such as neuraminidases, plasma proteins, avidins, streptavidins, chalones, cavitands, thyroglobulin, intrinsic factor, globulins, chelators, surfactants, organometallic substances, staphylococcal protein A, protein G, ribosomes, bacteriophages, cytochromes, lectins, certain resins, and organic polymers.
- Receptors also include various substances such as any proteins with selective affinity for ligands that are produced through recombinant DNA and genetic and molecular engineering.
- the carrier molecule may also include at least one lysis agent connected to the biocompatible hydrophilic backbone or to a bound polycationic polymer.
- the lysis agent could be any membrane fusion peptide or protein.
- the lysis agent can be selected to break down a biological membrane such as a cell, endosomal, or nuclear membrane, thereby allowing the polyanionic macromolecule to be released into the cytoplasm or nucleus of the cell. As a result of the presence of the lysis agent, the membrane undergoes lysis, fusion, or both.
- Such lysis agents may include a viral peptide, a bacterial toxin, a lytic peptide, aleveolysin, bifermentolysin, boutulinolysin, capriciolysin, cereolysin O, chauveolysin, histolyticolysin O, pneumolysin, sealigerolysin, septicolysin O, sordellilysin, streptoslysin O, tenaolysin or thuringolysin O, and active fragments thereof.
- a lytic peptide is a chemical grouping which penetrates a membrane such that the structural organization and integrity of the membrane is lost.
- Lysis agent also include viruses and synthetic compounds that can break down a biological membrane. Fragments of the above listed lysis agents which will provide endosomal escape activity may also be employed in the present invention. Other peptides and proteins are known to cause the breakdown or fusion or biological membranes and may be used as a lysis agent within the scope of the invention. Jahn, R. & Sudhof, T., Annu. Rev Biochem 68: 863-911(1999); Pecheur, E.I., et al, J Membrane Biol. 167: 1-17 (1999).
- the polycationic polymer is covalently linked to the biocompatible backbone polymer by a linker.
- the targeting moiety and the lysis agent may also be covalently linked to the backbone polymer or the bound polycationic polymer by a linker.
- Such linkers can be a hydrocarbon chain, a PEG fragment, a polypeptide, a linear polymer containing an ester bond, a linear polymer containing an amide bond, a linear polymer containing a disulfide bond, a linear polymer containing a hydrozone bond, a linear polymer containing an oxime bond or a combination thereof.
- the linkers may either be biodegradable linkers or non-biodegradable linkers.
- biodegradable linkers are short peptides and disulfide linkers (-(CH 2 )xSS(CH 2 )x- wherein x is an integer of 2 to 8).
- Non-biodegradable linkers include hydrocarbon linkers such as -(CH 2 )n- or -(CH 2 CH 2 O)n- where n is an integer of 2 to 50.
- the linkers can have a length from about 2 to about 100 atoms. Linkers with a length of about 3 atoms to about 30 atoms can also be used.
- the linkers used to covalently link the polycationic polymer to the backbone polymer can be configured to allow for the controlled release complexed polyanionic macromolecule from the carrier.
- Controlled release indicates that the nucleic acid or other polyanionic macromolecule is released from the copolymer carrier complex only by cleavage of the linker that were used to synthesize the carrier. Thus, controlled release does not include the release of the polyanionic macromolecule by diffusion until the linkages are cleaved.
- Biodegradable linkers include, but are not limited to, two categories of bonds.
- a first category includes disulfide linkages and ester bonds. Disulfide linkages and ester bonds are known for covalent coupling of pharmaceutical compounds to polymers. However, this category of bonds has limited value for delivering pharmaceutical compounds in vivo because these bonds are subject to cleavage in the blood stream.
- the second category includes bonds that are generally cleaved after entering the cell (intracellular cleavage). This category of linkers are cleavable under acidic conditions like those found in lysosomes or by enzymes thereby allowing the pharmaceutical compound to be released intracellularly.
- Enzyme-sensitive linkers include polypeptides that contain amino acid sequences that make the polypeptide hydrophobic. These polypeptides are cleaved by specific enzymes such as cathepsins, found primarily inside the cell. Such polypeptides can be synthetic or naturally occurring peptides. Examples of suitable biodegradable polypeptide linkers are GlyPheLeuGly (SEQ. ID. NO.: 1) and GlyPhePheGly (SEQ. ID. NO.: 2).
- biodegradable linkage is a "hindered” or “protected” disulfide bond that sterically inhibits attack from thiolate ions.
- protected disulfide bonds are found in the coupling agents S-4-succinimidyloxycarbonyl-.alpha-.methyl benzyl thiosulfate (SMBT) and 4-succinimidyloxycarbonyl-.alpha-.methyl-.alpha.-(2-pyridyldithio) toluene (SMPT).
- SBT succinimidyloxycarbonyl-.alpha-.methyl benzyl thiosulfate
- SMPT 4-succinimidyloxycarbonyl-.alpha-.methyl-.alpha.-(2-pyridyldithio) toluene
- the biocompatible hydrophilic backbone can have a molecular weight that is selected to optimize the delivery of the polyanionic macromolecule to the cell.
- the backbone polymer has a molecular weight in the range from about 1 ,000 to about 1,000,000.
- a backbone polymer with a molecular weight in the range from about 5,000 to about 100,000 may also be used.
- a biocompatible hydrophilic backbone with a molecular weight of about 20,000 to about 40,000 can be used to deliver the polyanionic macromolecule to the cell.
- the molecular weight of the polycationic polymer can also be selected for optimal delivery of the polyanionic macromolecule to the target cell.
- the molecular weight can be in the range from about 100 about 100,000.
- the molecular weight of the polycationic polymer can be in the range from about 200 to about 10,000.
- a polycationic polymer with a molecular weight in the range from about 400 to about 2,000 can be used to deliver the polyanionic macromolecule to the cell.
- the present invention also relates to a complex for delivering a polyanionic macromolecule to a cell.
- the carrier molecule allows the complex to cross the cell wall and other biological barriers and gain access to the interior of the cell.
- the complex may have a carrier molecule as described above complex ed with a polyanionic macromolecule.
- the complex may be given to an animal in vivo or to a cell in culture.
- the complex allows the polyanionic macromolecule to be delivered to the a cell within the animal or cell culture.
- the polyanionic macromolecule can be selected from a number of macromolecules that are useful in the treatment of disease or in laboratory experimentation.
- the polyanionic macromolecule is a nucleic acid such as RNA, DNA, or a combination or derivative thereof.
- the nucleic acid can be, for example, genomic DNA, plasmid DNA, synthetic DNA, or RNA.
- the invention also provides a method of transporting a polyanionic macromolecule across the biological barriers of the cell.
- the cell may be for example a cell in a cell culture.
- the cell may be a cell within a multicellular organism such as a plant or an animal.
- the cell can be a cell derived from an organism such as hepatocytes, liver cells, kidney cells, brain cells, bone marrow cells, nerve cells, heart cells, spleen cells, stem cells and co-cultures of the above.
- the cells may be from established cell lines such a HepG Hep G2 and Hela cells.
- the method of delivering the polyanionic macromolecule to the cell includes complexing the polyanionic macromolecule to a carrier molecule of the present invention to create a complex.
- the cell is then contacted with the complexed carrier molecule to deliver the polyanionic macromolecule to the cell.
- the carrier complex may enter the cell by endocytocis and then escape from the vesicles to gain access to the cytoplasm of the cell. If the target cell is within a cell culture in vitro, the cell can be contacted with the complexed carrier molecule by providing the cells with a growth medium containing the polyanionic macromolecule/ca ⁇ ier complex or by inserting a solution containing the polyanionic macromolecule/carrier complex into the growth media.
- the contacting may occur by positioning the complex within the organism so that it has access to the target cell.
- the complex may be administered by injecting a solution containing the complex into the circulatory system of the organism.
- a carrier molecule with a targeting moiety attached will allow the complex to be directed to a target cell with a target corresponding to the targeting moiety.
- the polyainonic macromolecule/carrier complex may be administered to an organism by intramuscular, intraperitoneal, intraabdominal, subcutaneous, intravenous, and intraarterial delivery.
- polymeric carrier molecules of the invention are complex with a nucleic acid or other drugs, they form polymeric micelles.
- polymeric micelles Following intravenous administration, such polymeric micelles have been found to have a prolonged systemic circulation time. This prolonged circulation time is due to their small size and hydrophilic shell which minimize uptake by the mononuclear phagocyte system and to their high molecular weight which prevents renal excretion.
- Polymeric micelle incorporated drugs may accumulate in tumors to a greater extent than the free drug and show reduced distribution into untargeted areas such as the heart. Accumulation of polymeric micelles in malignant or inflamed tissues may be due to increased vascular permeability and impaired lymphatic drainage. The tumor vessels are more leaky and less permselective than normal vessels. Several in vivo studies have shown that polymeric micelles are able to improve the efficiency of anticancer drugs against leukemia and solid tumors.
- the EPR effect is considered as a passive targeting method, but drug targeting could be further increased by binding to targeting moieties such as antibodies or sugars or by introducing a polymer sensitive to variation in temperature or pH.
- Targeting micelles or pH sensitive micelles can serve for the delivery of drug to tumors, inflamed tissues or endosomal compartments, since they all are associated with a lower pH than normal tissue.
- a solution of the grafted copolymer that contains nucleic acid or other polyanionic macromolecules can administered to the cultured cells or the body.
- An important consideration in the usefulness of a carrier molecules is how much drug can be loaded into the carrier.
- the molar ratio of the nitrogen on the carrier copolymer to the phosphate on the nucleic acid should be considered.
- the N/P ratio in the complexes of the carrier polymer and nucleic acid molecules will be in the range of about 1 to about 50. More specifically, it is anticipated that for most uses the N/P ratio in the complexes will be in the range between about 2 to about 30. These ranges given above are not exclusive of the N/P ratio that may be used with the invention. As long as functionality is maintained, drug loadings outside of these ranges falls within the scope of the invention.
- PEG Polyethylene glycol
- the PEG has a number "m” of pendant propionic acid groups (PA) randomly grafted onto its backbone.
- PEG-mPA and anhydrous dichloromethane are combined with the protection of argon.
- DMAP 4-dimethylaminopyridine
- EDC l-[3-dimethylaminopropyl]-3-ethylcarbodiimide hydrochloride
- acetic acid is added to the clear mixture.
- the clear reaction mixture is then mixed with a solution of polyethylenimine (PEI) in anhydrous dimethylformamide (DMF) under the protection of argon.
- PEI polyethylenimine
- DMF dimethylformamide
- the mixture may be concentrated on a rotary evaporator to remove most of the DMF solvent.
- the resulting product can be purified and concentrated to produce a wax product.
- the crude wax product can be further purified on a gel filtration column to yield purified PEG-mPA-PEI.
- FIG IB the general synthesis of another carrier polymer of the present invention is illustrated.
- This carrier polymer is formed from a PEG backbone conjugated to PEI via a biodegradable polypeptide linker, GFLG.
- PEG-mPA is obtained as a starting material.
- the PEG-mPA is then converted to PEG-mPA-ONp.
- PEG-mPA-ONp is synthesized by dissolving PEG-mPA in anhydrous dichloromethane.
- the PEG-mPA-ONp product and GFLG tetrapeptide are then dissolved in anhydrous DMF. N,N-diisopropylethylamine (DIPEA) is added to this solution.
- DIPEA N,N-diisopropylethylamine
- the reaction mixture can be concentrated to remove excess solvent. Cold ethyl ether may be added to precipitate the product.
- the PEG-mPA-GFLG product is then purified.
- the PEG-mPA-GFLG product is reacted with polyethylenimine to form PEG-mPA-GLFG-PEI.
- PEI2K Mw - 1,800
- a dry 50 ml one necked flask was charged with 1.3 g of polyethylene glycol of mean molecular weight of about 20,000 with 15 pendant propionic acid groups (PEG20K-15PA) (-0.75 mmole pendant -COOH, dried overnight in vacuum in P 2 O 5 desiccator) and 10 ml anhydrous dichloromethane with the protection of argon.
- PEG20K-15PA polyethylene glycol of mean molecular weight of about 20,000 with 15 pendant propionic acid groups
- PEG20K-15PA pendant propionic acid groups
- Example 2 Synthesis of PEG20K-15PA-PEI800 (15 PEI 800 grafted PEG20K) Following the procedure of Example 1, 1.0 g of polyethylene glycol of mean molecular weight of about 20,000 with about 15 pendant propionic acid groups (PEG20K-15PA) reacted with polyethylenimine of mean molecular weight of about 800 (PEI800, 20 grams) to produce about 1.1 grams of PEI20K-15PA-PEI800.
- ⁇ -NMR analysis indicates that the copolymer contains about 30% (w/w) PEI, indicating that the average molecular weight of the copolymer is about 28,400, assuming the average molecular weight of the starting PEG15PA is 20,000.
- Example 3 Synthesis of PEG20K-8PA-PEI800 (8 PEI 800 grafted PEG-20K) Following the procedure of Example 1, 1.0 gram of Polyethylene glycol of mean molecular weight of about 20,000 with about 8 pendant propionic acid groups (PEG20K- 8PA) reacted with polyethylenimine of mean molecular weight of about 800 (PEI800, 20 grams) to produce about 1.2 grams of PEI20K-8PA-PEI800.
- ⁇ -NMR analysis indicates that the copolymer contains about 11.5% (w/w) PEI, which indicating that the average molecular weight of the copolymer is about 22,607, assuming the average molecular weight of the starting PEG-8PA is 20,000.
- the solution was ultrafiltrated to about 60 ml followed by diafiltration with 2000 ml of deion water on a Pall Filtron Minim Diafiltration system equipped with a Memrane Centramate with alOK NMWC membrane cassette (Pall Co ⁇ oration, East Hills, NY).
- the final product solution was concentrated on a rotary evaporator, about 4.5 grams of wax solid was obtained.
- the wax product was further purified by ether precipitation from methanol twice, about 4.1 grams of white powered PEG-10PA-PEI1200 was obtained.
- ⁇ -NMR analysis indicates that the copolymer contains about 20% (w/w) PEI, indicating that the average molecular weight of the copolymer is about 24,963, assuming the average molecular weight of the starting PEG- 1 OP A is 20,000 Dalton.
- ⁇ -NMR D 2 0, 400 MHz), • 3.4-3.8 (m, 100 (arbitrarily set), -CH 2 CH 2 O- of PEG), 2.4-3.2 (m, 29, -CH 2 CH 2 N- of PEI).
- PEG20K-15PA-GLFG-PEI400 was synthesized according to the illustrated scheme.
- PEG polyethylene glycol
- PEG20K-15PA-ONp was synthesized by dissolving polyethylene glycol (PEG) of mean molecular weight of about 20,000 with about 15 pendant propionic acid groups (PEG20K-15PA) (2.0 g, -1.5 mmole -
- the white solid was filtered, washed with 10 ml of ice cold 10% methanol/isopropanol and 10 ml of room temperature of ethyl ether.
- the product was briefly dried with a stream of argon followed by drying in vacuum P 2 O 5 desiccator overnight.
- the purified PEG30K-15PA-GFLG product was reacted with PEI400 to form PEG20K-15PA-GFLG-PEI400.
- About 1.0 gram of PEG20K-15PA-GFLG was reacted with about 20 grams of polyethylenimine of mean molecular weight of about 400 (PEI400) as describe in Example 1.
- About 1.1 grams of PEG20K-15PA-GFLG-PEI2K was obtained.
- ⁇ -NMR indicates that each copolymer molecule contains 2,000 PEI and 9.0 molecules of GFLG linker assuming the average molecular weight of the starting PEG15PA is 20,000.
- Example 8 Synthesis of PEG20K-8PA-GFLG-PEI400 (8 PEI400 grafted PEG20K with GFLG linkers) Following the procedure of Example 5, PEG20K-8PA reacted with GFLG and polyethylenimine 400 (PEI400) to produce PEG20K-8PA-GFLG-PEI400.
- ⁇ -NMR indicates that each copolymer molecule contains 1,087 PEI and 3.8 molecules of GFLG linker, assuming the average molecular weight of the starting PEG-8PA is 20,000.
- HT1080 cells were seeded on a 6-well tissue culture plate. The cells were seeded at about 100,000 cells per well in 1.0 ml of HyQ MEM/EBSS medium with 10% FBS. The plate was incubated overnight at 37 °C in a 5% CO 2 incubator. Next, the medium was removed by aspiration and 900 ⁇ L of fresh medium was added to each well.
- a transfection medium was prepared containing a complex of DNA and a carrier copolymer of the present invention.
- a solution of the carrier copolymer was created.
- the concentration of the carrier copolymer was normalized to about 0.6 mg/ml PEI in PBS buffer.
- a volume of the carrier copolymer solution ranging from about 2.0 ⁇ L to about 20 ⁇ L was added to about 100 ⁇ L of serum free media in a sterile tube.
- the resulting solution was incubated for about 10 minutes at room temperature.
- the solution was then mixed with about 2.0 ⁇ L of 1.0 ⁇ g/ ⁇ L of green fluorescent protein DNA (GFP) or red fluorescent protein DNA (RFP) solution and incubated 20 minute at room temperature to create a DNA/ca ⁇ er copolymer complex.
- GFP green fluorescent protein DNA
- RFP red fluorescent protein DNA
- the DNA/carrier copolymer complex was added drop wise to the cells in the 6 well plate. As the complex was added to the cells, the plate was gently rocked in all directions to mix the complex with the growth medium. The cells were then incubated for at least 24 hours at 37 ° C in a 5% CO 2 incubator. The cells were examined with a fluorescence microscope, or a FACS cell sorter. The transfection medium was removed by aspiration and fresh medium was added to preserve the cells. Table 1 shows the results of the transfection experiments using various carriers of the present invention and controls and plasmid GFP DNA. A plus indicates successful transfection and a minus indicates no transfection.
- a transfection medium was prepared containing the a complex of an oligonucleotide and the carrier copolymer of the present invention. A solution of the carrier copolymer was created. The concentration of the carrier copolymer was about 0.6 mg/ml PEI in PBS buffer.
- a volume ranging from about 2.0 ⁇ L to about 20 ⁇ L of the carrier copolymer solution was added to a volume of serum free media to make a total solution volume of 50 ⁇ L in a sterile tube.
- the resulting solution was incubated at room temperature for about 10 minutes.
- the solution was then mixed with about 2.0 ⁇ L of O.lmM oligonucleotide solution (22- mer, -0.7 mg/ml).
- the oligonucleotide contained was a 22-mer phosphodiester ohgonucloetide with a 3' inversion and 5' fluorescence labeling.
- the resulting transfection medium was then incubated for 20 minutes at room temperature.
- the transfection medium was added to the wells in the 96 well plate.
- the cells were then incubated at 37 °C in a 5% CO 2 incubator for about 6 hours. Next, the transfection medium was removed by aspiration and the cells were washed twice with about 100 ⁇ L of sterile PBS.
- the invention presents a novel class of polycation grafted polymeric carrier molecules.
- the novel polycation grafted copolymers exhibit substantial water solubility and a low level of toxicity.
- Certain embodiments of the invention uses PEG as a backbone polymer to which PEI fragments or other polycationic polymer fragments are attached.
- PEG is linear polymer with many useful properties, such as good solubility and good excretion kinetics.
- PEG is biocompatibility because of its minimal toxicity, immunogenicity and antigenicity.
- the polycationic polymer By conjugating a polycationic polymer to a biocompatible polymers such as PEG, the polycationic polymer can be rendered more soluble and less toxic. Additionally small polycationic polymer fragments are much less toxic than large molecular weight cationic polymers and could be easily cleared out from the body. Thus, by conjugating the small cationic polymers to a biocompatible backbone polymer carrier copolymers can be created that allow for delivery of therapeutics such as polyanionic macromolecules to cells.
- the carrier polymers of the present invention also provide enhanced stability of the complexed DNA/carrier copolymer stability.
- the carrier polymers of the present invention have also been to shown to have enhanced transfection activity compared to other DNA carrier polymers.
- the copolymers of this invention bind nucleic acids through ionic interaction to form a coreshell like micelle structure. This structure is stable and soluble in biological conditions due to the neutral hydrophilic shell formed by the biocompatible backbone polymer.
- the complex is stable in biological buffers, even with the presence of serum. As a result, the transfection activity is much higher than the unmodified polycation carriers, such as PEI, PLL or chitosan.
- the carriers of the present invention can be used to deliver drugs and other therapeutic agents to specifically targeted cells or tissues.
- the copolymer carrier can be used for the controlled release and targeted delivery of nucleic acids to a cell.
- the efficiency of a drug efficiency can be increased by targeting specific cells or organs, therefore reducing accumulation of the drug in healthy tissues and minimizing its toxicity. Such specific targeting allows higher doses of a therapeutic to be administered, if needed, without undesired effects on non targeted cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002345981A AU2002345981B2 (en) | 2001-11-28 | 2002-06-26 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
CA002468548A CA2468548A1 (en) | 2001-11-28 | 2002-06-26 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
EP02744728A EP1461436A4 (en) | 2001-11-28 | 2002-06-26 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
MXPA04005194A MXPA04005194A (en) | 2001-11-28 | 2002-06-26 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers. |
JP2003547617A JP2005510572A (en) | 2001-11-28 | 2002-06-26 | Polycationic water-soluble copolymers and methods for transporting polyanionic polymers through biological barriers |
HK05109969A HK1078103A1 (en) | 2001-11-28 | 2005-11-08 | Polycationic water soluble copolymer and method for transferring polyynionic macromolecules across biological barriers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/996,507 | 2001-11-28 | ||
US09/996,507 US7060498B1 (en) | 2001-11-28 | 2001-11-28 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003046185A1 true WO2003046185A1 (en) | 2003-06-05 |
Family
ID=25542997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/020565 WO2003046185A1 (en) | 2001-11-28 | 2002-06-26 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
Country Status (9)
Country | Link |
---|---|
US (1) | US7060498B1 (en) |
EP (1) | EP1461436A4 (en) |
JP (1) | JP2005510572A (en) |
CN (1) | CN1330765C (en) |
AU (1) | AU2002345981B2 (en) |
CA (1) | CA2468548A1 (en) |
HK (1) | HK1078103A1 (en) |
MX (1) | MXPA04005194A (en) |
WO (1) | WO2003046185A1 (en) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006098463A1 (en) * | 2005-03-14 | 2006-09-21 | Shinka Soyaku Inc. | Polynucleic acid-binding substance |
EP1765403A2 (en) * | 2004-05-10 | 2007-03-28 | University of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
EP1807054A2 (en) * | 2004-11-03 | 2007-07-18 | Expression Genetics, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
EP1859812A1 (en) * | 2005-02-10 | 2007-11-28 | The University of Tokyo | Polycation chargeable polymer and use as carrier of nucleic acid |
KR100806601B1 (en) * | 2004-09-17 | 2008-02-28 | 재단법인서울대학교산학협력재단 | Degradable linear Polyethylenimine-co-Polyether Copolymers as a Novel Gene Carrier |
WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
WO2009055487A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
WO2009114854A1 (en) * | 2008-03-14 | 2009-09-17 | Egen, Inc. | Biodegradable cross-linked branched poly (alkylene imines) |
WO2009140679A2 (en) | 2008-05-16 | 2009-11-19 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
CN101298501B (en) * | 2008-04-23 | 2011-08-24 | 武汉大学 | High polymer nano-particle containing carboxyl, preparation and use thereof |
WO2011163436A1 (en) | 2010-06-24 | 2011-12-29 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
WO2012047631A2 (en) | 2010-09-27 | 2012-04-12 | The Children's Hospital Of Philadelphia | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012118910A2 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US8299236B2 (en) | 2004-05-04 | 2012-10-30 | Marina Biotech, Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
EP2518509A2 (en) | 2008-03-05 | 2012-10-31 | The Regents of the University of California | Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP. |
EP2522753A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
WO2013010998A2 (en) | 2011-07-15 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compositions and methods for immunomodulation |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
EP2589961A2 (en) | 2006-09-06 | 2013-05-08 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
WO2013106494A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
WO2014043289A2 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
WO2014043292A1 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
US8710209B2 (en) | 2009-12-09 | 2014-04-29 | Nitto Denko Corporation | Modulation of HSP47 expression |
WO2014138687A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Peptides and compositions for treatment of joint damage |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
EP2902013A1 (en) | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2015175487A1 (en) | 2014-05-13 | 2015-11-19 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
WO2016176745A1 (en) | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US9587249B2 (en) | 2008-10-27 | 2017-03-07 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9994915B2 (en) | 2010-10-11 | 2018-06-12 | Sanford-Burnham Medical Research Institute | miR-211 expression and related pathways in human melanoma |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10543232B2 (en) | 2014-05-14 | 2020-01-28 | Targimmune Therapeutics Ag | Polyplex of double-stranded RNA and polymeric conjugate |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
EP3808763A1 (en) | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
US11234994B2 (en) | 2016-04-14 | 2022-02-01 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL154044A0 (en) * | 2000-07-21 | 2003-07-31 | Essentia Biosystems Inc | Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
TR201815364T4 (en) * | 2004-03-03 | 2018-11-21 | Revance Therapeutics Inc | Topical application and transdermal distribution of botulinum toxins. |
MXPA06009897A (en) | 2004-03-03 | 2008-02-07 | Revance Therapeutics Inc | Compositions and methods for topical diagnostic and therapeutic transport. |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
US8168222B2 (en) | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
ES2443229T3 (en) | 2004-12-22 | 2014-02-18 | Nitto Denko Corporation | Drug carrier and drug carrier kit for fibrosis inhibition |
KR101453963B1 (en) | 2005-03-03 | 2014-10-22 | 레반스 테라퓨틱스, 아이엔씨. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
ZA200707351B (en) * | 2005-03-03 | 2010-02-24 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
BRPI0618753A2 (en) * | 2005-11-17 | 2011-09-13 | Revance Therapeutics Inc | composition for transdermal release of botulinum toxin and method of administration |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
US20080233152A1 (en) * | 2006-12-29 | 2008-09-25 | Revance Therapeutics, Inc. | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabilized with Polypeptide Fragments Derived from HIV-TAT |
KR20090102833A (en) * | 2006-12-29 | 2009-09-30 | 레반스 테라퓨틱스, 아이엔씨. | Transport molecules using reverse sequence hiv-tat polypeptides |
KR100825519B1 (en) * | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | A chitosan based polymer conjugate and a method for producing the same |
TWI407971B (en) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
LT2178549T (en) * | 2007-07-26 | 2017-01-25 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
CN101970012A (en) | 2007-09-14 | 2011-02-09 | 日东电工株式会社 | Drug carriers |
WO2009062084A2 (en) * | 2007-11-07 | 2009-05-14 | University Of Utah Research Foundation | Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery |
GB0723714D0 (en) * | 2007-12-04 | 2008-01-16 | Cambridge Entpr Ltd | Supramolecular handcuffs in polymeric architecture |
US8344116B2 (en) * | 2008-03-17 | 2013-01-01 | Case Western Reserve University | Polymers and complexes for delivery of nucleic acids to intracellular targets |
JP5814793B2 (en) * | 2008-11-25 | 2015-11-17 | エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) | Block copolymer and use thereof |
CN102154349B (en) * | 2010-12-30 | 2014-08-06 | 江苏大学 | Cationized mulberry polysaccharide nanoparticle gene vectors and manufacturing method thereof |
CN102154350B (en) * | 2010-12-30 | 2012-08-29 | 江苏大学 | Nanoparticle gene delivery system of cationized lycium barbarum polysaccharides and preparation method thereof |
ES2755782T3 (en) | 2011-07-26 | 2020-04-23 | Cambridge Entpr Ltd | Supramolecular capsules |
CN104245801B (en) | 2012-02-20 | 2020-06-23 | 剑桥实业有限公司 | Cucurbituril-based hydrogels |
GB201301648D0 (en) | 2013-01-30 | 2013-03-13 | Cambridge Entpr Ltd | Nested supramolecular capsules |
MX370929B (en) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Compositions and methods for safe treatment of rhinitis. |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US10232050B1 (en) | 2014-12-12 | 2019-03-19 | Clemson University | Multi-functional particles and methods of using the same |
US11633355B2 (en) | 2014-12-12 | 2023-04-25 | Clemson University Research Foundation | Multi-functional particles and methods of using the same |
CN107432935A (en) * | 2017-09-12 | 2017-12-05 | 四川大学 | A kind of cationic polymer/TDNs carries medicine compound and preparation method thereof |
CN112135838A (en) * | 2018-03-29 | 2020-12-25 | 日油株式会社 | Degradable polyethylene glycol conjugates |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567410A (en) * | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5714166A (en) * | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
YU45837B (en) | 1988-01-18 | 1992-07-20 | LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. | PROCEDURE FOR PREPARATION OF THE NEW NICARDIPINE INCLUSION COMPLEX OZ. ITS HYDROCHLORIDE WITH BETA-CYCLODEXTRIN |
IT1241417B (en) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS |
US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
ES2221920T3 (en) | 1992-04-03 | 2005-01-16 | The Regents Of The University Of California | SELF-ASSEMBLY POLYUCLEOTID RELEASE SYSTEM THAT INCLUDES AN AMPHIPATIC CATIONIC PEPTIDE. |
US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5777078A (en) * | 1993-04-28 | 1998-07-07 | Worcester Foundation For Experimental Biology | Triggered pore-forming agents |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
FR2739292B1 (en) | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | PHARMACEUTICAL COMPOSITION USEFUL FOR TRANSFECTING NUCLEIC ACIDS AND USES THEREOF |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
DE19726186A1 (en) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Complexes for the transport of nucleic acid into higher eukaryotic cells |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
-
2001
- 2001-11-28 US US09/996,507 patent/US7060498B1/en not_active Expired - Fee Related
-
2002
- 2002-06-26 CN CNB02827640XA patent/CN1330765C/en not_active Expired - Fee Related
- 2002-06-26 EP EP02744728A patent/EP1461436A4/en not_active Withdrawn
- 2002-06-26 WO PCT/US2002/020565 patent/WO2003046185A1/en active Application Filing
- 2002-06-26 CA CA002468548A patent/CA2468548A1/en not_active Abandoned
- 2002-06-26 JP JP2003547617A patent/JP2005510572A/en not_active Withdrawn
- 2002-06-26 MX MXPA04005194A patent/MXPA04005194A/en not_active Application Discontinuation
- 2002-06-26 AU AU2002345981A patent/AU2002345981B2/en not_active Ceased
-
2005
- 2005-11-08 HK HK05109969A patent/HK1078103A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714166A (en) * | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US5567410A (en) * | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
Non-Patent Citations (2)
Title |
---|
MING ET AL.: "Surface modifications of alginate/poly(lolysine) microcapsular membranes with poly(ethylene glycol) and poly(vinyl alcohol)", BIOMATERIALS, vol. 16, no. 8, May 1995 (1995-05-01), pages 649 - 655, XP004032947 * |
See also references of EP1461436A4 * |
Cited By (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8299236B2 (en) | 2004-05-04 | 2012-10-30 | Marina Biotech, Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
EP1765403A2 (en) * | 2004-05-10 | 2007-03-28 | University of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
EP1765403A4 (en) * | 2004-05-10 | 2011-03-30 | Univ Utah Res Found | Combined active and passive targeting of biologically active agents |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
KR100806601B1 (en) * | 2004-09-17 | 2008-02-28 | 재단법인서울대학교산학협력재단 | Degradable linear Polyethylenimine-co-Polyether Copolymers as a Novel Gene Carrier |
EP1807054A4 (en) * | 2004-11-03 | 2008-07-23 | Expression Genetics Inc | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
JP2008519128A (en) * | 2004-11-03 | 2008-06-05 | エクスプレッション・ジェネティックス・インコーポレーテッド | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making the same |
EP1807054A2 (en) * | 2004-11-03 | 2007-07-18 | Expression Genetics, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US8445017B2 (en) | 2004-11-03 | 2013-05-21 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
EP1859812A4 (en) * | 2005-02-10 | 2010-08-25 | Univ Tokyo | Polycation chargeable polymer and use as carrier of nucleic acid |
EP1859812A1 (en) * | 2005-02-10 | 2007-11-28 | The University of Tokyo | Polycation chargeable polymer and use as carrier of nucleic acid |
WO2006098463A1 (en) * | 2005-03-14 | 2006-09-21 | Shinka Soyaku Inc. | Polynucleic acid-binding substance |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
EP2679998A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2589961A2 (en) | 2006-09-06 | 2013-05-08 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2680000A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2679999A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2494993A2 (en) | 2007-05-04 | 2012-09-05 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
EP2522752A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522753A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522755A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522754A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2924435A2 (en) | 2007-10-22 | 2015-09-30 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
WO2009055487A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
EP2518509A2 (en) | 2008-03-05 | 2012-10-31 | The Regents of the University of California | Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP. |
WO2009114854A1 (en) * | 2008-03-14 | 2009-09-17 | Egen, Inc. | Biodegradable cross-linked branched poly (alkylene imines) |
CN101298501B (en) * | 2008-04-23 | 2011-08-24 | 武汉大学 | High polymer nano-particle containing carboxyl, preparation and use thereof |
WO2009140679A2 (en) | 2008-05-16 | 2009-11-19 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes |
EP2902013A1 (en) | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
EP3495488A1 (en) | 2008-10-27 | 2019-06-12 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
US9587249B2 (en) | 2008-10-27 | 2017-03-07 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP3012324A2 (en) | 2009-12-09 | 2016-04-27 | Nitto Denko Corporation | Modulation of hsp47 expression |
US8710209B2 (en) | 2009-12-09 | 2014-04-29 | Nitto Denko Corporation | Modulation of HSP47 expression |
US10093923B2 (en) | 2009-12-09 | 2018-10-09 | Nitto Denko Corporation | Modulation of HSP47 expression |
EP3434773A2 (en) | 2009-12-09 | 2019-01-30 | Nitto Denko Corporation | Modulation of hsp47 expression |
US9206424B2 (en) | 2009-12-09 | 2015-12-08 | Nitto Denko Corporation | Modulation of HSP47 expression |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
WO2011163436A1 (en) | 2010-06-24 | 2011-12-29 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP4079856A1 (en) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
EP3372684A1 (en) | 2010-08-24 | 2018-09-12 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012047631A2 (en) | 2010-09-27 | 2012-04-12 | The Children's Hospital Of Philadelphia | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
US9994915B2 (en) | 2010-10-11 | 2018-06-12 | Sanford-Burnham Medical Research Institute | miR-211 expression and related pathways in human melanoma |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EP3327125A1 (en) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012118910A2 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US9044420B2 (en) | 2011-04-08 | 2015-06-02 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP3048111A1 (en) | 2011-07-15 | 2016-07-27 | Fundació Institut de Recerca Biomèdica de Bellvitge | Compositions and methods for immunomodulation |
EP2557089A2 (en) | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
WO2013010998A2 (en) | 2011-07-15 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compositions and methods for immunomodulation |
WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
WO2013106494A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
WO2014043292A1 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
WO2014043289A2 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
EP3391900A1 (en) | 2013-03-08 | 2018-10-24 | Novartis AG | Peptides and compositions for treatment of joint damage |
WO2014138687A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Peptides and compositions for treatment of joint damage |
WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
WO2015175487A1 (en) | 2014-05-13 | 2015-11-19 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
US10543232B2 (en) | 2014-05-14 | 2020-01-28 | Targimmune Therapeutics Ag | Polyplex of double-stranded RNA and polymeric conjugate |
US11298376B2 (en) | 2014-05-14 | 2022-04-12 | Targimmune Therapeutics Ag | Method of treating cancer |
WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
WO2016176745A1 (en) | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US11234994B2 (en) | 2016-04-14 | 2022-02-01 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
US11427621B2 (en) | 2016-07-15 | 2022-08-30 | Institucio Catalana De Recerca I Estudis Avancats | Methods and compositions for the treatment of cancer |
WO2018011433A1 (en) | 2016-07-15 | 2018-01-18 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Methods and compositions for the treatment of cancer |
EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
EP3808763A1 (en) | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
WO2021074449A1 (en) | 2019-10-17 | 2021-04-22 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compounds for immunomodulation |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2023069987A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Rejuvenation treatment of age-related white matter loss cross reference to related application |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CN1330765C (en) | 2007-08-08 |
AU2002345981A1 (en) | 2003-06-10 |
MXPA04005194A (en) | 2005-06-20 |
HK1078103A1 (en) | 2006-03-03 |
US7060498B1 (en) | 2006-06-13 |
CA2468548A1 (en) | 2003-06-05 |
JP2005510572A (en) | 2005-04-21 |
EP1461436A1 (en) | 2004-09-29 |
EP1461436A4 (en) | 2006-03-22 |
CN1617928A (en) | 2005-05-18 |
AU2002345981B2 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7060498B1 (en) | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers | |
US8324365B2 (en) | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof | |
US7001891B1 (en) | Biodegradable polycation composition for delivery of an anionic macromolecule | |
US8969543B2 (en) | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof | |
CA2420495C (en) | A novel cationic lipopolymer as biocompatible gene delivery agent | |
US20040142474A1 (en) | Novel cationic lipopolymer as a biocompatible gene delivery agent | |
AU2004211522B2 (en) | Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems | |
US20030147958A1 (en) | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents | |
US20020141965A1 (en) | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents | |
US20020146826A1 (en) | Cationic polysaccharide compositions | |
US20080051323A1 (en) | Chloroquine drug compositions and methods for their synthesis | |
US20050153913A1 (en) | Nucleic acid carrier compositions and methods for their synthesis | |
JP2011524446A (en) | Chitosan oligosaccharide fatty acid graft product modified with polyglycol, its preparation method and use thereof | |
US20060040879A1 (en) | Chloroquine coupled nucleic acids and methods for their synthesis | |
US20060014695A1 (en) | Hpma-polyamine conjugates and uses therefore | |
IL291916A (en) | Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics | |
KR20010069179A (en) | Cationic lipids for gene transfer and Preparation Method thereof | |
US20040086481A1 (en) | Cationic polymer-nucleic acid complexes and methods of making them | |
Aldawsari | Preparation and evaluation of amino acid-bearing polymers for enhanced gene expression in tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2468548 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/005194 Country of ref document: MX Ref document number: 2003547617 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002345981 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002744728 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002827640X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002744728 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002345981 Country of ref document: AU Date of ref document: 20020626 Kind code of ref document: B |